文献速递慢性肾脏病遗传性与小管间质肾病肾血管病与高血压

儿童多囊肾病:现状与未来展望

Polycystic Kidney Disease in Children: The Current Status and the Next Horizon.
PubMed 文献 · Am J Kidney Dis · 2025-03-18

本文综述常染色体显性多囊肾病(ADPKD)与隐性多囊肾病(ARPKD)在发病机制、诊断与临床评估上的重叠与差异,强调两者可贯穿胎儿至成人各年龄段发病,并提出胎儿至婴儿、青春期至成人两个关键过渡期的诊疗原则,同时总结成人试验对儿童研究设计的启示。

要点

  • ADPKD与ARPKD均可跨越胎儿至成人全年龄段发病,需警惕年龄标签误导。
  • 两者共享纤毛功能障碍与细胞内信号失调机制,诊断需结合影像与遗传。
  • 胎儿至婴儿、青春期至成人是诊疗过渡关键节点,现有文献覆盖不足。

核心结论

  • ADPKD与ARPKD虽经典发病年龄不同,但均可贯穿全生命周期发病,需按过渡期原则管理。
  • 尽管PKD尚无治愈手段,发病机制研究已发现 promising 治疗靶点,正于多项临床试验中评估。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • ADPKD与ARPKD共享肾囊肿、高血压、尿浓缩缺陷及进展性慢性肾脏病等特征。
  • 两者共同致病机制包括纤毛功能障碍与细胞内信号失调。
  • ADPKD传统视为成人起病,ARPKD经典描述为婴儿或儿童期疾病,但均可各年龄段发病。
  • 胎儿至婴儿、青春期至成人两个过渡期在现有文献中覆盖不足。
  • 近期临床试验多基于成人人群,对儿童研究设计有启示。

关键数值与推荐

  • 提出胎儿至婴儿、青春期至成人两个关键过渡期的临床诊疗指导原则。

临床怎么用

  • 临床应打破ADPKD仅成人、ARPKD仅儿童的年龄刻板印象,全年龄段评估PKD可能。
  • 关注胎儿至婴儿、青春期至成人两个过渡节点的诊疗衔接与遗传咨询。
  • 儿童PKD研究设计可参考成人试验成果,但需专门儿童研究验证。

局限性

  • 摘要未报告综述的检索策略、纳入文献范围及证据等级。
  • 现有临床试验主要基于成人人群,儿童数据有限。
  • 胎儿至婴儿、青春期至成人过渡期在现有文献中覆盖不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are inherited disorders that share many features such as kidney cysts, hypertension, urinary concentrating defects, and progressive chronic kidney disease. The underlying pathogenic mechanisms for both include cilia dysfunction and dysregulated intracellular signaling. ADPKD has been traditionally regarded as an adult-onset disease whereas ARPKD has been classically described as an infantile or childhood condition. However, clinicians must recognize that both disorders can present across all age groups, ranging from fetal life and infancy to childhood and adolescence as well as adulthood. Here we highlight the points of overlap and distinct features for these disorders with respect to pathogenesis, diagnostic modalities (radiological and genetic), clinical assessment, and early therapeutic management. In particular, we consider key issues at 2 critical points for transition of care: fetal life to infancy and adolescence to adulthood. These time points are poorly covered in the extant literature. Therefore, we recommend guiding principles for transitions of clinical care at these critical junctures in the life span. Although there is no cure for polycystic kidney disease (PKD), recent insights into pathogenic mechanisms have identified promising therapeutic targets that are currently being evaluated in a growing portfolio of clinical trials. We summarize the key findings from these largely adult-based trials and discuss the implications for designing child-focused studies. Finally, we look forward to the next horizon for childhood PKD, highlighting gaps in our current knowledge and discussing future directions and strategies to attenuate the full burden of disease for children affected with PKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Cadnapaphornchai MA, Dell KM, Gimpel C, et al. Polycystic Kidney Disease in Children: The Current Status and the Next Horizon. Am J Kidney Dis. 2025. PMID: 40113156. doi:10.1053/j.ajkd.2025.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。